Craft

Advanced
Eutilex

Eutilex

Stock Price

₩2.4 K

2024-10-29

Market Capitalization

₩85 B

2024-10-29

Revenue

₩131.7 M

FY, 2023

Eutilex Summary

Company Summary

Overview
Eutilex ((주)유틸렉스) is a biotech company developing anti-tumor T-cell therapy. Additionally, it offers antibody therapeutics based on its proprietary immunotherapy technology.
Type
Public
Status
Active
Founded
2015
HQ
KR | view all locations
Website
http://eutilex.com/en/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Table of Contents

Key People

  • Byoung S. Kwon

    Byoung S. Kwon, CEO

    • Soo Young Choi

      Soo Young Choi, COO

      • Edwin E. Kwon

        Edwin E. Kwon, CFO

        • Jeonghoon Han

          Jeonghoon Han, CBO

          LocationsView all

          1 location detected

          • Seoul HQ

            Korea (Republic of)

            25 Gasan digital 1-ro, Geumcheon-gu

          Eutilex Financials

          Summary Financials

          Revenue (Q3, 2024)
          ₩6.9B
          Gross profit (Q3, 2024)
          ₩2.4B
          Net income (Q3, 2024)
          (₩18.4B)
          Cash (FY, 2023)
          ₩30.3B
          EBIT (Q3, 2024)
          (₩18.9B)
          Enterprise value
          $80.2B

          Competitors and Similar Companies

          Compare competitors

          Footer menu

          Product

          Solutions

          Resources

          Company

          © Craft.co 2025
          Share price data provided by IEX